|
|
|
|
|
|
|
|
|
|
CONCLUSIONS:
Single agent bevacizumab has activity in ovarian cancer patients. Pre-treatment serum VEGF seems to have predictive value.
Tuesday, May 18, 2010
The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab (Avastin)
CONCLUSIONS:
Single agent bevacizumab has activity in ovarian cancer patients. Pre-treatment serum VEGF seems to have predictive value.
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.